---
title: "Ascendis Pharma posts PaTHway trial Week 182 TransCon PTH data presentation for hypoparathyroidism adults"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289673147.md"
description: "Ascendis Pharma presented Week 182 data from the Phase 3 PaTHway trial of TransCon PTH for adult hypoparathyroidism. Results showed 96% achieved independence from conventional therapy and 89% had normal serum calcium. Renal function improved with increased eGFR, and urine calcium normalized early. Safety updates noted serious treatment-emergent adverse events in 25% of participants."
datetime: "2026-06-13T20:09:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289673147.md)
  - [en](https://longbridge.com/en/news/289673147.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289673147.md)
---

# Ascendis Pharma posts PaTHway trial Week 182 TransCon PTH data presentation for hypoparathyroidism adults

-   Ascendis published Week 182 results from the Phase 3 PaTHway trial of TransCon PTH in adults with hypoparathyroidism. \* At Week 182, 96% met criteria for independence from conventional therapy; 89% had normal albumin-adjusted serum calcium. \* Mean 24-hour urine calcium normalized by Week 26, remaining within the normal range through Week 182. \* Renal function improved, with mean eGFR up 10.97 mL/min/1.73 m2 from baseline at Week 182. \* Safety update showed serious TEAEs in 25% of participants; treatment-related events included injection-site reactions in 25%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on June 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ASND.US](https://longbridge.com/en/quote/ASND.US.md)

## Related News & Research

- [Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism | ASND Stock News](https://longbridge.com/en/news/289673083.md)
- [TD Asset Management Inc Has $49.90 Million Position in Ascendis Pharma A/S $ASND](https://longbridge.com/en/news/288928427.md)
- [Norges Bank Invests $25.33 Million in Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/289298330.md)
- [Assessing Veeva Systems (VEEV) Valuation After Recent Share Price Weakness And Fair Value Gap](https://longbridge.com/en/news/289441327.md)
- [Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss](https://longbridge.com/en/news/289671714.md)